Propanc Biopharma Files 8-K
Ticker: PPCB · Form: 8-K · Filed: Apr 10, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Apr 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Reporting
TL;DR
Propanc Biopharma filed an 8-K on 4/10/24 for routine reporting.
AI Summary
Propanc Biopharma, Inc. filed an 8-K on April 10, 2024, reporting other events and financial statements. The company, incorporated in Delaware, has its principal executive office in Camberwell, Victoria, Australia. This filing does not contain specific financial details or significant business updates beyond the reporting of these items.
Why It Matters
This 8-K filing indicates Propanc Biopharma is reporting routine events and financial statements to the SEC, which is standard corporate practice.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- April 10, 2024 (date) — Date of Report
FAQ
What is the purpose of this 8-K filing by Propanc Biopharma, Inc.?
The 8-K filing on April 10, 2024, is for reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was Propanc Biopharma, Inc. incorporated?
Propanc Biopharma, Inc. was incorporated in Delaware.
What is the principal executive office address for Propanc Biopharma, Inc.?
The principal executive office is located at 302, 6 Butler Street, Camberwell, VIC, 3124, Australia.
What is the IRS Employer Identification Number for Propanc Biopharma, Inc.?
The IRS Employer Identification Number is 33-0662986.
What is the SIC code for Propanc Biopharma, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 423 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-04-10 16:20:00
Filing Documents
- form8-k.htm (8-K) — 34KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 301KB
- ex99-1_002.jpg (GRAPHIC) — 705KB
- ex99-1_003.jpg (GRAPHIC) — 146KB
- ex99-1_004.jpg (GRAPHIC) — 351KB
- ex99-1_005.jpg (GRAPHIC) — 321KB
- ex99-1_006.jpg (GRAPHIC) — 228KB
- ex99-1_007.jpg (GRAPHIC) — 271KB
- ex99-1_008.jpg (GRAPHIC) — 88KB
- ex99-1_009.jpg (GRAPHIC) — 259KB
- ex99-1_010.jpg (GRAPHIC) — 286KB
- ex99-1_011.jpg (GRAPHIC) — 365KB
- ex99-1_012.jpg (GRAPHIC) — 310KB
- ex99-1_013.jpg (GRAPHIC) — 273KB
- ex99-1_014.jpg (GRAPHIC) — 284KB
- ex99-1_015.jpg (GRAPHIC) — 262KB
- ex99-1_016.jpg (GRAPHIC) — 477KB
- ex99-1_017.jpg (GRAPHIC) — 428KB
- ex99-1_018.jpg (GRAPHIC) — 225KB
- ex99-1_019.jpg (GRAPHIC) — 367KB
- ex99-1_020.jpg (GRAPHIC) — 284KB
- ex99-1_021.jpg (GRAPHIC) — 224KB
- ex99-1_022.jpg (GRAPHIC) — 298KB
- ex99-1_023.jpg (GRAPHIC) — 330KB
- ex99-1_024.jpg (GRAPHIC) — 245KB
- ex99-1_025.jpg (GRAPHIC) — 249KB
- ex99-1_026.jpg (GRAPHIC) — 352KB
- 0001493152-24-014213.txt ( ) — 11138KB
- ppcb-20240410.xsd (EX-101.SCH) — 3KB
- ppcb-20240410_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240410_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 10, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer